Patents by Inventor John F. Lyons

John F. Lyons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Logic puzzle
    Publication number: 20090096160
    Abstract: A logic puzzle having a shaped game space with edges defining an overall shape, within which are included a plurality of shaped subsets, each having an equal multiplicity of subdivided segments or cells that collectively provide for a preliminary solution set and a final solution set, with the final solution set realized when each of the shaped subsets includes a preliminary solution set and when the preliminary solution set is also formed in a predetermined pattern across multiple shaped subsets.
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Inventor: John F. Lyons, JR.
  • Three-dimensional logic puzzle
    Publication number: 20090091079
    Abstract: A three-dimensional logic puzzle having a multiplicity of face sides wherein a final solution set is provided by forming a preliminary solution set on each of the face sides and across the face sides in a predetermined pattern.
    Type: Application
    Filed: October 5, 2007
    Publication date: April 9, 2009
    Inventor: John F. Lyons, JR.
  • RAF-MEK-ERK pathway inhibitors to treat cancer
    Patent number: 7307071
    Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: December 11, 2007
    Assignee: Onyx Pharmaceuticals, Inc
    Inventors: John F. Lyons, Gideon Bollag
  • RAF-MEK-ERK pathway inhibitors to treat cancer
    Publication number: 20030125359
    Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
    Type: Application
    Filed: December 3, 2002
    Publication date: July 3, 2003
    Inventors: John F. Lyons, Gideon Bollag